Disease · MONDO_0008383
Comparisons in its trials390
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 390
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Etanercept vs nbDMARDs: serious adverse events | 944 of 3,529 | 744 of 2,864 | 6,393 | NCT01646385 | Trial comparisons |
| Celecoxib vs Oral Diclofenac Plus Omeprazole: Number of Subjects With Clinically Significant Upper and/or Lower Gastrointestinal Events (CSULGIEs) | 20 of 2,238 | 81 of 2,246 | 4,484 | NCT00141102 | Trial comparisons |
| Celecoxib vs Oral Diclofenac Plus Omeprazole: Number of Subjects With Moderate to Severe Abdominal Symptoms | 132 of 2,238 | 162 of 2,246 | 4,484 | NCT00141102 | Trial comparisons |
| Celecoxib vs Oral Diclofenac Plus Omeprazole: Number of Subjects With SUs | 5 of 2,238 | 11 of 2,246 | 4,484 | NCT00141102 | Trial comparisons |
| Celecoxib vs Oral Diclofenac Plus Omeprazole: Number of Subjects With CSULGIES or Symptomatic Ulcers (SUs) | 25 of 2,238 | 92 of 2,246 | 4,484 | NCT00141102 | Trial comparisons |
| Celecoxib vs Oral Diclofenac Plus Omeprazole: Number of Subjects Withdrawn Due to GI Adverse Events (AEs) | 114 of 2,238 | 167 of 2,246 | 4,484 | NCT00141102 | Trial comparisons |
| Celecoxib vs Oral Diclofenac Plus Omeprazole: serious adverse events | 61 of 2,223 | 61 of 2,237 | 4,460 | NCT00141102 | Trial comparisons |
| Celecoxib vs Oral Diclofenac Plus Omeprazole: Number of Subjects With a Clinically Significant Decrease From Baseline in Hematocrit and/or Hemoglobin | 45 of 2,184 | 123 of 2,167 | 4,351 | NCT00141102 | Trial comparisons |
| Celecoxib vs Oral Diclofenac Plus Omeprazole: Number of Subjects Hospitalized in Last 6 Months at the Post Trial Interview | 82 of 2,047 | 79 of 2,048 | 4,095 | NCT00141102 | Trial comparisons |
| Celecoxib vs Oral Diclofenac Plus Omeprazole: Number of Subjects Alive at the Post Trial Interview | 2,018 of 2,047 | 2,023 of 2,048 | 4,095 | NCT00141102 | Trial comparisons |
| Etanercept vs Tocilizumab: serious adverse events | 422 of 1,542 | 479 of 1,538 | 3,080 | NCT01331837 | Trial comparisons |
| Otilimab 90 mg vs Otilimab 150 mg: Number of Participants With Anti-GSK3196165 Antibodies | 11 of 1,456 | 10 of 1,459 | 2,915 | NCT04333147 | Trial comparisons |
| Otilimab 90 mg vs Otilimab 150 mg: deaths from any cause | 10 of 1,456 | 9 of 1,459 | 2,915 | NCT04333147 | Trial comparisons |
| Otilimab 90 mg vs Otilimab 150 mg: serious adverse events | 123 of 1,456 | 114 of 1,459 | 2,915 | NCT04333147 | Trial comparisons |
| Treatment Arm 1: OKZ 64 mg q4w + MTX vs Treatment Arm 2: OKZ 64 mg q2w + MTX: Incidence of Treatment-Emergent AEs Leading to Withdrawal of the Study Treatment | 87 of 1,043 | 90 of 1,061 | 2,104 | NCT03120949 | Trial comparisons |
| Treatment Arm 1: OKZ 64 mg q4w + MTX vs Treatment Arm 2: OKZ 64 mg q2w + MTX: deaths from any cause | 13 of 1,043 | 13 of 1,061 | 2,104 | NCT03120949 | Trial comparisons |
| Treatment Arm 1: OKZ 64 mg q4w + MTX vs Treatment Arm 2: OKZ 64 mg q2w + MTX: serious adverse events | 129 of 1,043 | 120 of 1,061 | 2,104 | NCT03120949 | Trial comparisons |
| Sarilumab + Disease Modifying Anti-Rheumatic Drugs (DMARD) vs Sarilumab Monotherapy: deaths from any cause | 49 of 1,910 | 3 of 111 | 2,021 | NCT01146652 | Trial comparisons |
| Sarilumab + Disease Modifying Anti-Rheumatic Drugs (DMARD) vs Sarilumab Monotherapy: serious adverse events | 617 of 1,910 | 27 of 111 | 2,021 | NCT01146652 | Trial comparisons |
| Etanercept vs nbDMARDs: serious adverse events | 77 of 211 | 534 of 1,543 | 1,754 | NCT01557322 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0008383/comparisons